TopLead Bio Announces FDA Clearance to Initiate Clinical Trials for TollB-001, a Novel Class 1.1 Small Molecule Drug for Rheumatoid Arthritis

Beijing Tuoling Botai Biotechnology Co., Ltd. recently received formal written notification from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for TollB-001 tablets, a Class 1.1 novel drug for rheumatoid arthritis, has been officially approved by the FDA, allowing clinical trials to be conducted in the United States.This marks another milestone for Tuoling Botai’s TollB-001 tablets following their acceptance by China’s Center for Drug Evaluation (CDE), representing a significant step in Tuoling Botai’s international commercialization strategy and expansion into overseas markets.

Rheumatoid arthritis is a chronic systemic disease of unknown etiology, characterized primarily by inflammatory synovitis. It can lead to joint deformity and loss of function, and is also known as “undying cancer.” Rheumatoid arthritis is one of the leading causes of work disability and impairment among the Chinese population. Currently, the average annual overall economic burden on patients with rheumatoid arthritis is significantly higher than that of other common chronic diseases such as hypertension and diabetes. Moreover, existing medications suffer from issues such as insufficient response rates and significant toxic side effects, creating an urgent need for the development of novel therapeutics with new mechanisms of action.

TollB-001 tablets are the first Class 1.1 small-molecule new drug developed by Toplead Biotech for the treatment of rheumatoid arthritis. Preclinical studies have demonstrated that its efficacy and safety profile are significantly superior to those of first-line clinical therapies. As an orally administered novel drug independently developed by Toplead Biotech with a novel mechanism of action, it is the only small-molecule agent among competitors targeting the same pathway to achieve target selectivity, thereby addressing or mitigating the limitations of existing therapeutic options for rheumatoid arthritis.

Professor Yin Hang, Founder of Tuoling Botai and Professor at the School of Pharmaceutical Sciences, Tsinghua University, stated, “Tuoling Botai has always been committed to providing patients with better innovative drugs to address clinical needs and challenges. We are delighted to see the approval of TollB-001 tablets for clinical trials in the United States, which marks a significant milestone in Tuoling Botai’s R&D pipeline. Moving forward, we will fully advance the clinical development of TollB-001 tablets and further expand their indications, aiming to provide superior therapeutic options and regimens for more patients with autoimmune diseases.”

Beijing Tuoling Botai Biotechnology Co., Ltd. was founded in 2020 by Professor Yin Hang from the School of Pharmaceutical Sciences at Tsinghua University. The company is dedicated to providing patients with innovative therapies that modulate human immune responses, addressing critical unmet needs in the global market for immunomodulatory drugs. Leveraging nearly two decades of accumulated expertise in the mechanisms of immune regulation and the development of immunomodulatory therapeutics, Tuoling Botai utilizes cutting-edge drug discovery technologies and platforms to innovatively identify novel immune regulatory mechanisms and multiple small-molecule immunomodulatory drugs. The company has secured exclusive licenses for numerous small-molecule drug patents, with coverage spanning major pharmaceutical R&D countries and regions worldwide. It has established and is rapidly advancing multiple pipelines focused on drug development for autoimmune diseases. Its lead small-molecule candidate for rheumatoid arthritis has demonstrated significantly superior efficacy and safety profiles compared to first-line clinical treatments and has entered clinical trials.

Since its inception, TopLead Biotech has garnered extensive attention from the industry. It has been selected for the National Key Special Project – Disruptive Technology Project Library, and has obtained certifications as a Technology-based Small and Medium-sized Enterprise (SME) from the Ministry of Science and Technology, a Zhongguancun High-tech Enterprise, and an Innovative SME in Beijing. The company has successfully completed its angel round and Series A financing, raising a total of nearly RMB 200 million. It has also received numerous awards, including the Grand Prize at the National Disruptive Technology Innovation Competition Final organized by the Ministry of Science and Technology; the Outstanding Enterprise Award at the China Innovation and Entrepreneurship Competition National Finals and the Second Prize in Beijing; the Third Prize in Beijing and the Second Prize in Haidian District at the China “Chuangyi” Innovation and Entrepreneurship Competition; the Challenge Award at the Tsinghua President’s Cup Innovation and Entrepreneurship Competition; recognition as one of the VB-Find Award 2022 Top 100 Most Innovative Medical Technology Products (Solutions); the “Golden Horse Award” on the 2022 China Biopharmaceutical Industry Chain Innovation List for both “2022 Most Promising Startup” and “2022 Most Watched Emerging Enterprise”; a TOP 150 ranking in the Beijing Regional Competition of “Maker Beijing 2022” Innovation and Entrepreneurship Competition; and the Third Prize at the inaugural Digital Intelligence New Industry Healthcare Entrepreneurship Competition, among many other honors.